Last Friday, the
New York Times reported that J&J has restructured, organizing its operations along three major categories of therapies:
- treatments for pain, inflectious diseases, CNS, metabolic and cardiovascular diseases
- immune-related
- virology-related.
Overseeing all R&D, commercial and operations activites for the company's pharmaceuticals group will be Joseph Scodari.